MI+ (cases)(n = 41) | MI− (controls)(n = 181) | p Value | |
Age at censoring | 67.5 (10.0) | 56.0 (12.3) | 0.000 |
Disease duration (years)* | 4.31 (1.1–8.5) | 3.04 (1.3–9.2) | 0.371 |
Male gender (%) | 21 (51.2) | 56 (30.9) | 0.014 |
DAS28 (baseline) | 5.21 (1.3) | 4.98 (1.3) | 0.192 |
Time-averaged DAS28 | 4.00 (1.2) | 3.94 (1.1) | 0.737 |
DAS28 AUC | 181 (62–308) | 149 (70–409) | 0.692 |
Last DAS28 | 3.62 (1.4) | 3.86 (1.5) | 0.335 |
ESR (baseline) | 32.5 (16.3–50.0) | 26.0 (12.0–50.5) | 0.228 |
Time-averaged ESR | 17.9 (10.5–30.2) | 17.6 (8.5–27.8) | 0.213 |
Last ESR | 17.3 (12.6) | 20.8 (19.4) | 0.789 |
CRP (baseline) (mg/l) | 22.0 (5.5–44.5) | 12.0 (2.2–43.5) | 0.186 |
Time-averaged CRP (mg/l) | 6.4 (2.0–18.8) | 5.3 (1.2–14.3) | 0.475 |
Last CRP | 10.3 (13.0) | 16.5 (30.4) | 0.876 |
Time-averaged 28-swollen joints | 6.3 (2.5–8.4) | 7.5 (4.5–10.2) | 0.156 |
HAQ-DI (baseline) | 0.72 (0.7) | 0.57 (0.5) | 0.398 |
BMI | 27.3 (3.9) | 25.4 (4.2) | 0.007 |
RF positive (%) | 36 (87.8) | 153 (84.5) | 0.595 |
Ever smoker (%) | 27 (65.9) | 103 (56.9) | 0.294 |
Hypertension (%) | 14 (34.1) | 32 (17.7) | 0.019 |
DM (%) | 4 (9.8) | 14 (7.7) | 0.669 |
CVD in family (%) | 22 (53.7) | 78 (43.1) | 0.220 |
TC (baseline) (mmol/l) | 5.39 (1.0) | 4.99 (0.9) | 0.035 |
HDL (baseline) (mmol/l) | 0.84 (0.2) | 0.94 (0.3) | 0.035 |
LDL (baseline) (mmol/l) | 3.87 (0.9) | 3.38 (0.9) | 0.002 |
TG (baseline) (mmol/l) | 1.75 (0.7) | 1.54 (0.7) | 0.040 |
Atherogenic index (TC/HDL) | 6.77 (1.87) | 5.68 (1.74) | 0.001 |
Values are mean (SD), median (p25–p75) or number (%). p Values in bold indicate a significant difference.
*Time from baseline (diagnosis of RA) until event (cases) or censoring (controls).
AUC, area under the curve; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; DAS28, disease activity score; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RF, rheumatoid factor; TC, total cholesterol; TG, triglyceride.